Kura Oncology (KURA) is forecast to grow revenue at 42.7% per year, far outpacing the US market average of 10.5% per year. However, the company remains unprofitable with losses increasing at a 15.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback